Bharat Immunolog

Which are the latest news on Bharat Immunolog?

Why is Bharat Immunological & Biological Corporation Ltd falling/rising?

As of 05-Sep, Bharat Immunological & Biological Corporation Ltd's stock price has risen slightly to 15.34, indicating a potential trend reversal after previous declines. However, the stock has been underperforming over various time frames, with significant year-to-date and annual losses, alongside declining investor participation.

As of 05-Sep, Bharat Immunological & Biological Corporation Ltd's stock price is rising slightly, with a current price of 15.34, reflecting a change of 0.03 (0.2%) upward. This increase comes after the stock experienced two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 1.17% today, which may contribute to the positive movement in its price.<BR><BR>However, it is important to note that despite this recent uptick, the stock has been underperforming over various time frames. For instance, it has declined by 3.28% over the past week and 5.19% over the past month. Year-to-date, the stock is down 23.57%, and it has seen a significant drop of 30.43% over the past year. Furthermore, the stock is trading below its moving averages across multiple periods, indicating a generally bearish trend.<BR><BR>Investor participation appears to be falling, as evidenced by a decrease in delivery volume, which was down by 28.76% against the 5-day average. This decline in participation could suggest a lack of confidence among investors, despite the slight rise in price today. Overall, while there is a minor increase in the stock price today, the broader context shows a persistent downward trend and declining investor interest.

Who are in the management team of Bharat Immunolog?

The management team of Bharat Immunolog includes Y K Gupta (Chairman), Sandip K Lal (Company Secretary), and several Independent Directors: Alka Sharma, Mohd Aslam, Sudhanshu Vrati, Madhu Dikshit, and Pankaj Kumar, along with Managing Director Sanjay Kumar Mishra.

The management team of Bharat Immunolog includes the following individuals:<BR><BR>1. **Y K Gupta** - Chairman & Independent Director<BR>2. **Sandip K Lal** - Company Secretary & Compliance Officer<BR>3. **Alka Sharma** - Independent Director<BR>4. **Mohd Aslam** - Independent Director<BR>5. **Sudhanshu Vrati** - Independent Director<BR>6. **Madhu Dikshit** - Independent Director<BR>7. **Sanjay Kumar Mishra** - Managing Director<BR>8. **Pankaj Kumar** - Independent Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Bharat Immunolog do?

Bharat Immunological & Biological Corporation Ltd (BIBCOL) manufactures vaccines and pharmaceutical products as a micro-cap company under the Department of Biotechnology. As of September 2023, it reported a net loss of 5 Cr and has a market cap of INR 69 Cr.

Overview:<BR>Bharat Immunological & Biological Corporation Ltd (BIBCOL) is engaged in the manufacture of vaccines and pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>BIBCOL was incorporated in 1989 and operates as a Central Public Sector Unit under the Department of Biotechnology, Ministry of Science and Technology. The latest quarterly results reported are for September 2023.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -5 Cr (Quarterly Results - Sep 2023)<BR>Market-cap value: INR 69 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A (Loss Making)<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.83<BR>Return on Equity: -22.96%<BR>Price to Book: 0.87<BR><BR>Contact Details:<BR>Address: BIBCOL OPV Plant Village Chola, Bulandshahr, Uttar Pradesh: 203203<BR>Tel: 91-5732-238210<BR>Website: http://www.bibcol.com

Who are the peers of the Bharat Immunolog?

Bharat Immunolog's peers include Vineet Laborator, Sunil Healthcare, Samrat Pharma, and others, with varying management risks and growth rates. Phaarmasia leads in 1-year returns at 192.54%, while Bharat Immunolog has a 1-year return of -27.90%.

Peers: The peers of Bharat Immunolog are Vineet Laborator, Sunil Healthcare, Samrat Pharma, Source Natural, Phaarmasia, Biofil Chemicals, Zenith Drugs, Ajooni Biotech, Vilin Bio Med, and Onyx Biotec.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vineet Laborator, Sunil Healthcare, Phaarmasia, Zenith Drugs, Ajooni Biotech, and Vilin Bio Med, while Average management risk is found at Samrat Pharma and Biofil Chemicals, and the rest. Good growth is noted at Sunil Healthcare and Ajooni Biotech, Average growth at Phaarmasia and Vilin Bio Med, and the rest show Below Average growth. Excellent capital structure is present at Samrat Pharma, Good capital structure at Source Natural and Biofil Chemicals, while Below Average capital structure is seen at Vineet Laborator, Sunil Healthcare, Phaarmasia, Bharat Immunolog, Zenith Drugs, and the rest.<BR><BR>Return Snapshot: Phaarmasia has the highest 1-year return at 192.54%, while Samrat Pharma has the lowest at -25.91%, with Bharat Immunolog's own 1-year return at -27.90%, indicating it performs worse than Samrat Pharma. Additionally, Vineet Laborator, Biofil Chemicals, and Bharat Immunolog all have negative six-month returns.

How big is Bharat Immunolog?

As of 31st August, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 69.00 Cr and reported Net Sales of 7.65 Cr with a Net Profit loss of 18.07 Cr over the latest four quarters. Shareholder's Funds were 87.80 Cr and Total Assets were 158.84 Cr as of March 2023.

As of 31st August, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 69.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Bharat Immunological reported Net Sales of 7.65 Cr. However, it faced a loss of 18.07 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2023. Shareholder's Funds stood at 87.80 Cr, while Total Assets were valued at 158.84 Cr.

Who are the top shareholders of the Bharat Immunolog?

The top shareholders of Bharat Immunolog include the President of India, who holds 59.25% of the shares, while individual investors own 39.47%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Bharat Immunolog are primarily the promoters, with the President of India holding the largest share at 59.25%. Additionally, individual investors collectively hold 39.47% of the shares. There are currently no mutual funds or foreign institutional investors involved in the company's shareholding.

Is Bharat Immunolog overvalued or undervalued?

As of April 5, 2023, Bharat Immunolog is considered overvalued and classified as "risky" due to negative financial metrics, including a PE Ratio of -6.21 and an EV to EBITDA of -10.01, which compare unfavorably to peers like Sun Pharma and Cipla, alongside a 1-year stock return of -8.84% versus the Sensex's 7.62%.

As of 5 April 2023, Bharat Immunolog has moved from a grade of "does not qualify" to "risky." The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of -6.21, an EV to EBITDA of -10.01, and a Price to Book Value of 1.43. These figures indicate significant financial distress, particularly highlighted by the negative PE and EV ratios.<BR><BR>In comparison to its peers, Bharat Immunolog's valuation appears unfavorable. For instance, Sun Pharma has a PE Ratio of 35.25, while Cipla stands at 22.99, both indicating a more favorable market perception. The company's recent stock performance has also lagged behind the Sensex, with a 1-year return of -8.84% compared to the Sensex's 7.62%. Overall, the combination of poor financial ratios and unfavorable peer comparisons suggests that Bharat Immunolog is overvalued in the current market environment.

What is the technical trend for Bharat Immunolog?

As of May 13, 2025, Bharat Immunolog's trend is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands across different time frames.

As of 13 May 2025, the technical trend for Bharat Immunolog has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the Bollinger Bands show a bullish signal on the weekly chart but mildly bearish on the monthly. The KST is mildly bullish weekly but bearish monthly, and there are no clear trends indicated by Dow Theory on both weekly and monthly time frames. Overall, the current stance is mildly bearish, driven primarily by the mixed signals from moving averages and the monthly MACD.

How has been the historical performance of the Bharat Immunolog?

Bharat Immunolog has experienced a declining trend in net sales and profitability, with net sales dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, and losses increasing from Rs 6.75 crore to Rs 17.06 crore in the same period. Despite a positive cash flow from operating activities in March 2023, the overall financial position remains weak.

Answer:<BR>The historical performance of Bharat Immunolog shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Bharat Immunolog's net sales have decreased from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, reflecting a downward trend over the years. The total operating income followed a similar pattern, dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023. The company has faced increasing raw material costs, which peaked at Rs 84.28 crore in March 2019 and fell to Rs 33.04 crore in March 2023. Operating profit margins have deteriorated significantly, with an operating profit margin of -41.38% in March 2023 compared to a positive margin of 9.9% in March 2017. The profit before tax has also worsened, moving from a profit of Rs 9.45 crore in March 2017 to a loss of Rs 22.85 crore in March 2023. Consequently, the profit after tax has shown a similar decline, with losses increasing from Rs 6.75 crore in March 2017 to Rs 17.06 crore in March 2023. The company's total liabilities decreased from Rs 191.70 crore in March 2022 to Rs 158.84 crore in March 2023, while total assets also fell from Rs 191.70 crore to Rs 158.84 crore in the same period. Cash flow from operating activities turned positive in March 2023 at Rs 10.00 crore, contrasting with a negative cash flow of Rs -42.00 crore in March 2022, although the overall cash position remains weak with a closing cash balance of Rs 1.00 crore in March 2023.

When is the next results date for Bharat Immunolog?

No Upcoming Board Meetings

Has Bharat Immunolog declared dividend?

No Dividend History Available

Should I buy, sell or hold Bharat Immunolog?